RELAPSED PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus-Immunotherapy combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-hIFNβ-NIS) combined with an immunotherapy drug (cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the immunotherapy he…
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
New combo therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted drug) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to treatment. About 24 adults in Singapore will receive the drugs intravenou…
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC